We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+0.86%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
+$121M
Cap. Flow
+$179M
Cap. Flow %
11.83%
Top 10 Hldgs %
46.72%
Holding
103
New
28
Increased
19
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$70.7M
2
UNH icon
UnitedHealth
UNH
+$33M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.5M
4
ELV icon
Elevance Health
ELV
+$28.2M
5
JBIO
Jade Biosciences
JBIO
+$27.1M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$22.4M
2
HOLX
Hologic
HOLX
+$18.7M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.7M
4
MRUS
Merus
MRUS
+$16.3M
5
INSM icon
Insmed
INSM
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.75%
2 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
51
Iovance Biotherapeutics
IOVA
$1.97B
$5.61M 0.37%
3,261,707
-4,523,293
-58% -$11.3M
IDYA icon
52
IDEAYA Biosciences
IDYA
$3.49B
$5.25M 0.35%
+250,000
New +$4.8M
IMUX icon
53
Immunic
IMUX
$194M
$5.09M 0.34%
729,301
– –
QDEL icon
54
QuidelOrtho
QDEL
$1.17B
$5.01M 0.33%
+174,000
New +$5.14M
SRRK icon
55
Scholar Rock
SRRK
$5.72B
$4.43M 0.29%
125,000
-160,000
-56% -$5.02M
NSPR icon
56
InspireMD
NSPR
$32.3M
$4.28M 0.28%
1,886,207
+940,831
+100% +$2.34M
ETON icon
57
Eton Pharmaceutcials
ETON
$1.25B
$4.06M 0.27%
+285,000
New +$4.51M
CGON icon
58
CG Oncology
CGON
$6.3B
$4.03M 0.27%
155,000
-148,585
-49% -$3.58M
VSTM icon
59
Verastem
VSTM
$505M
$3.88M 0.26%
935,909
– –
EPIX
60
DELISTED
ESSA Pharma
EPIX
$3.85M 0.25%
2,262,026
– –
AKRO
61
DELISTED
Akero Therapeutics
AKRO
$3.84M 0.25%
72,000
-45,000
-38% -$2.04M
TRVI icon
62
Trevi Therapeutics
TRVI
$2.65B
$3.83M 0.25%
+700,000
New +$4.36M
TNGX icon
63
Tango Therapeutics
TNGX
$4.73B
$3.74M 0.25%
+730,000
New +$1.8M
TNDM icon
64
Tandem Diabetes Care
TNDM
$1.38B
$3.73M 0.25%
200,000
-296,039
-60% -$5.86M
WGS icon
65
GeneDx Holdings
WGS
$2.13B
$3.69M 0.24%
+40,000
New +$3.14M
ANIP icon
66
ANI Pharmaceuticals
ANIP
$1.81B
$3.31M 0.22%
50,743
-173,941
-77% -$11.3M
MURA
67
DELISTED
Mural Oncology
MURA
$3.27M 0.22%
+1,323,877
New +$3.12M
ADMA icon
68
ADMA Biologics
ADMA
$2.07B
$3.19M 0.21%
+175,000
New +$3.57M
CTMX icon
69
CytomX Therapeutics
CTMX
$716M
$2.96M 0.2%
+1,304,300
New +$2.1M
OFIX icon
70
Orthofix Medical
OFIX
$492M
$2.91M 0.19%
261,147
-340,778
-57% -$4.22M
ERAS icon
71
Erasca
ERAS
$6.47B
$2.75M 0.18%
2,162,162
– –
DNLI icon
72
Denali Therapeutics
DNLI
$3.83B
$2.55M 0.17%
182,110
+47,110
+35% +$663K
XENE icon
73
Xenon Pharmaceuticals
XENE
$6.19B
$2.47M 0.16%
+78,800
New +$2.57M
MDGL icon
74
Madrigal Pharmaceuticals
MDGL
$11.8B
$2.42M 0.16%
8,000
-59,500
-88% -$17.7M
VCEL icon
75
Vericel Corp
VCEL
$2.36B
$2.17M 0.14%
+50,953
New +$2.12M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Soleus Capital Management held 103 positions worth $1.51B, up 8.7% from $1.39B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Soleus Capital Management deployed $179M of net new capital in Q2 2025, opening 28 new positions and adding to 19 existing holdings. Its largest new stake was UnitedHealth: 86,250 shares worth $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was TG Therapeutics, an estimated $22.4M trimmed.

  • Soleus Capital Management's largest Q2 2025 buy was UnitedHealth: 86,250 shares worth $26.9M.
  • Soleus Capital Management added most to Krystal Biotech in Q2 2025, an estimated $70.7M increase.
  • Soleus Capital Management's biggest Q2 2025 reduction was TG Therapeutics, cutting an estimated $22.4M.
  • Soleus Capital Management fully exited Hologic in Q2 2025, selling an estimated $18.7M.
  • Soleus Capital Management's ten largest holdings make up 47% of its $1.51B portfolio in Q2 2025.
  • Soleus Capital Management opened 28 new positions and closed 8 in Q2 2025.
  • Soleus Capital Management's portfolio value rose 8.7% quarter-over-quarter to $1.51B.

Based on Soleus Capital Management's 13F filing for Q2 2025, filed 15 Aug 2025.